Revolution Medicines RVMD
The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday
Pancreatic cancer is often diagnosed after it has spread, leaving patients with just months to live. But in trials, RevMed’s drug nearly doubled typical survival time for those with an aggressive form of the disease. In a late-stage study published in May, patients who received chemotherapy — the current standard of treatment — lived for just 6.7 months, while those given Rasonque lived for more than 13 months.
The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday
Pancreatic cancer is often diagnosed after it has spread, leaving patients with just months to live. But in trials, RevMed’s drug nearly doubled typical survival time for those with an aggressive form of the disease. In a late-stage study published in May, patients who received chemotherapy — the current standard of treatment — lived for just 6.7 months, while those given Rasonque lived for more than 13 months.